Q-omics provides the consensus-scored DSCAML1 profile across patient tissues and cancer cell-line models. DSCAML1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DSCAML1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, DSCAML1 RNA expression shows 17,059 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, COAD, and KIRP as cancer lineages where DSCAML1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DSCAML1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DSCAML1 survival associations across molecular data types. DSCAML1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DSCAML1 RNA expression–survival associations across cancer types. High DSCAML1 expression shows unfavorable associations in UCEC, but favorable associations in SKCM, MESO, LGG, KIRC and COAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for DSCAML1 RNA expression.
This table summarizes DSCAML1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for DSCAML1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DSCAML1 shows lower tumor expression in COAD, LUSC, UCEC and BLCA and higher tumor expression in KIRC and KIRP. The COAD box plot shows higher DSCAML1 RNA expression in normal versus tumor tissue (log2 FC = −0.947, t-test p < 0.001).
This table shows molecular features associated with DSCAML1 in patient tissues and cancer cell lines. In patient samples, DSCAML1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DSCAML1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
